An investigation into Oscar Health Inc. (NYSE:OSCR)’s technical aspects

The price of Oscar Health Inc. (NYSE: OSCR) closed at $3.10 in the last session, up 4.38% from day before closing price of $2.97. In other words, the price has increased by $+0.1300 from its previous closing price. On the day, 768284 shares were traded. OSCR stock price reached its highest trading level at $3.1000 during the session, while it also had its lowest trading level at $2.9100.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



We take a closer look at OSCR’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.30 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.72. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.28.

Upgrades & Downgrades

On November 14, 2022, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight but kept the price unchanged to $5.

BofA Securities Downgraded its Neutral to Underperform on June 15, 2022, whereas the target price for the stock was revised from $6 to $4.50.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 06 when Quane Alessandrea C. sold 17,456 shares for $2.64 per share. The transaction valued at 46,052 led to the insider holds 165,801 shares of the business.

Blackley Richard Scott sold 31,397 shares of OSCR for $82,832 on Dec 06. The Chief Transformation Officer now owns 334,750 shares after completing the transaction at $2.64 per share. On Dec 02, another insider, Baltrus Victoria, who serves as the Chief Accounting Officer of the company, sold 2,789 shares for $2.84 each. As a result, the insider received 7,910 and left with 20,673 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.18 while its Price-to-Book (P/B) ratio in mrq is 0.61.

Stock Price History:

Over the past 52 weeks, OSCR has reached a high of $10.52, while it has fallen to a 52-week low of $2.05. The 50-Day Moving Average of the stock is 2.6730, while the 200-Day Moving Average is calculated to be 4.9090.

Shares Statistics:

According to the various share statistics, OSCR traded on average about 1.75M shares per day over the past 3-months and 1.13M shares per day over the past 10 days. A total of 212.82M shares are outstanding, with a floating share count of 177.46M. Insiders hold about 0.40% of the company’s shares, while institutions hold 88.30% stake in the company. Shares short for OSCR as of Oct 13, 2022 were 8.65M with a Short Ratio of 8.03M, compared to 9.18M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.08% and a Short% of Float of 7.90%.

Earnings Estimates

The company has 6 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.73 for the current quarter, with a high estimate of -$0.63 and a low estimate of -$0.8, while EPS last year was -$1.02. The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.7 and low estimates of -$1.16.

Analysts are recommending an EPS of between -$2.34 and -$2.81 for the fiscal current year, implying an average EPS of -$2.58. EPS for the following year is -$1.53, with 6 analysts recommending between -$1.27 and -$1.73.

Revenue Estimates

According to 2 analysts, the current quarter’s revenue is expected to be $962.16M. It ranges from a high estimate of $975M to a low estimate of $949.33M. As of the current estimate, Oscar Health Inc.’s year-ago sales were $414.21M, an estimated increase of 132.30% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $925.2M, an increase of 86.50% less than the figure of $132.30% in the same quarter last year. There is a high estimate of $946M for the next quarter, whereas the lowest estimate is $904.39M.

A total of 3 analysts have provided revenue estimates for OSCR’s current fiscal year. The highest revenue estimate was $3.91B, while the lowest revenue estimate was $3.62B, resulting in an average revenue estimate of $3.79B. In the same quarter a year ago, actual revenue was $1.84B, up 106.30% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $4.5B in the next fiscal year. The high estimate is $4.67B and the low estimate is $4.24B. The average revenue growth estimate for next year is up 18.70% from the average revenue estimate for this year.